Summary & Overview
HCPCS J7643: Glycopyrrolate Inhalation Solution, Compounded, DME, Per mg
HCPCS Level II code J7643 represents compounded glycopyrrolate inhalation solution supplied in unit-dose form and billed per milligram when administered via durable medical equipment. This code captures a specialized respiratory medication modality used for inhalation therapy where compounded formulations are required. It matters nationally as inhaled anticholinergic agents and compounded respiratory products are relevant to chronic obstructive and other airway management strategies and can affect DME billing and medication cost structures.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, the typical sites of service, and which payers commonly adjudicate this code. The publication summarizes common billing practices, payer coverage considerations, and comparable HCPCS coding scenarios.
The report outlines benchmarks for utilization and reimbursement where available, highlights policy updates affecting HCPCS-level billing for compounded inhalation products, and provides clinical context about use of inhaled glycopyrrolate via DME. Data not available in the input is noted where applicable. The content is intended to inform coding specialists, billing managers, and policy analysts about operational and payer-focused aspects of HCPCS Level II code J7643.
Billing Code Overview
HCPCS Level II code J7643 describes glycopyrrolate, inhalation solution, compounded product, administered through DME, unit dose form, per milligram. The service type is administration of a compounded inhalation anticholinergic medication supplied via durable medical equipment. The typical site of service is outpatient settings where DME is used, including home administration with DME support, outpatient infusion/respiratory clinics, and other ambulatory sites that furnish inhalation therapy via DME.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with chronic obstructive pulmonary disease (COPD) or chronic bronchitis who requires inhaled anticholinergic bronchodilator therapy delivered via a device supplied as durable medical equipment (DME). The patient presents to a pulmonary clinic or home health infusion/respiratory therapy service where a pharmacist compounds unit-dose glycopyrrolate inhalation solution per the prescribing orders. The clinical workflow: the pulmonologist documents the indication and dose in the medical record and sends the prescription to the pharmacy; the pharmacy compounds the unit-dose product in milligram strength and labels it for administration through the patient’s DME nebulizer; respiratory therapy or home health staff verify device compatibility, perform initial patient education on nebulizer use and inhalation technique, and document administration or supply for home use. Billing uses HCPCS Level II code J7643 reported per milligram for the compounded unit-dose product; supplies, DME rental or purchase, and professional services may be billed separately using appropriate DME and service codes. Patient follow-up includes assessment of symptom control, inhalation technique, device maintenance, and adverse effects such as dry mouth or urinary retention.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier |